Key result
Aortic valve neocuspidization demonstrates acceptable safety and durability with ~97% freedom from reoperation at five years.
Why the study?
Multicentre data describing the mid-term functional durability of aortic valve neocuspidization in real-world populations remain limited.
Does aortic valve neocuspidization provide durable clinical and echocardiographic outcomes in patients requiring aortic valve surgery?
Cohort (n=672)
Yes
Does aortic valve neocuspidization provide durable clinical and echocardiographic outcomes in patients requiring aortic valve surgery?
Aortic valve neocuspidization demonstrates acceptable safety and stable mid-term clinical and echocardiographic durability up to 5-7 years in a real-world multicenter cohort.
OBJECTIVES: Aortic valve neocuspidization (AVNeo) has gained widespread recognition in clinical practice; however, multicentre data describing its mid-term functional durability in real-world populations remain limited. This study aimed to evaluate the clinical and echocardiographic outcomes of AVNeo in a large multicentre cohort with extended follow-up. METHODS: This retrospective multicentre study included 672 patients who underwent AVNeo at 16 institutions. The study population was characterized by advanced age, small body size, and a substantial burden of comorbidities. Mid-term outcomes included overall survival, freedom from reoperation, and longitudinal echocardiographic performance assessed from discharge through mid-term follow-up. Survival analyses were performed using the Kaplan-Meier method, and temporal echocardiographic changes were evaluated using linear mixed-effects models accounting for repeated measurements and center-level clustering. RESULTS: Early postoperative outcomes demonstrated acceptable procedural safety, with a 30-day mortality of 3.0%. Echocardiographic assessment showed functional optimization during the first postoperative year, while effective orifice area remained stable. Beyond 1 year, transvalvular gradients, peak velocity, valve area, and ventricular function remained stable up to 7 years after surgery. Estimated overall survival was 91.7% at 1 year and 79.5% at 5 years, while freedom from reoperation remained high at 99.4% at 1 year and 96.5% at 5 years. CONCLUSIONS: In this large multicentre real-world cohort, AVNeo demonstrated stable mid-term valve performance without evidence of clinically significant progressive deterioration. These findings support the durability and reproducibility of AVNeo in routine clinical practice.
No takes yet. Share an insight, caveat, or question.
Ueno et al. (2026) conducted a cohort in Aortic valve disease (n=672). Aortic valve neocuspidization (AVNeo) was evaluated on Overall survival at 5 years. Aortic valve neocuspidization demonstrated acceptable safety and durability, with a 5-year overall survival of 79.5% and 5-year freedom from reoperation of 96.5%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: